Annexon

Update in progress

ANNX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Annexon is a clinical‑stage biopharmaceutical company that discovers and develops medicines for inflammatory diseases. Its lead program, Tanruprubart, a full‑length monoclonal antibody, is in Phase 3 for Guillain‑Barré syndrome, has completed Phase II for Huntington’s disease, and is in Phase 2a for ALS. ANX007 (Fab) is in Phase 3 for geographic atrophy; ANX1502 is an oral small‑molecule in Phase 1 for autoimmune indications; ANX009 (C1q Fab) is in Phase I for lupus nephritis. Founded 2011, based in Brisbane, California.

Company score

Sentiment: 0.27; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.23; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.18; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive